These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33817946)

  • 1. Impact of extended dual antiplatelet therapy on long-term prognosis in patients with acute coronary syndrome complicated with anemia: A sub-analysis of the real-world OPT-CAD study.
    Zhao Y; Li J; Ma S; Jiang Z; Li Z; Wang X; Han Y; Li Y
    Catheter Cardiovasc Interv; 2021 Aug; 98(2):E235-E242. PubMed ID: 33817946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dual antiplatelet therapy prolongation in acute coronary syndrome patients with both high ischemic and bleeding risk: insight from the OPT-CAD study.
    Na K; Qiu M; Wei N; Li J; Yan C; Li J; Li Y; Han Y
    Front Cardiovasc Med; 2023; 10():1201091. PubMed ID: 37745130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Impact of prolonging dual antiplatelet therapy on long-term prognosis of elderly patients with coronary heart disease complicated with diabetes mellitus undergoing drug-eluting stent implantation].
    Xu JJ; Zhu P; Song Y; Yuan DS; Jia SD; Zhao XY; Yao Y; Jiang L; Xu N; Li JX; Zhang Y; Song L; Gao LJ; Chen JL; Qiao SB; Yang YJ; Xu B; Gao RL; Yuan JQ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 May; 50(5):450-457. PubMed ID: 35589593
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of dual antiplatelet therapy duration on 1-year clinical outcomes in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: Insights from the real-world OPT-CAD study.
    Li J; Li Y; Qiu M; Li Z; Yang J; Wang X; Bao D; Wang X; Han Y
    Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():579-586. PubMed ID: 31872515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis.
    Valgimigli M; Smits PC; Frigoli E; Bongiovanni D; Tijssen J; Hovasse T; Mafragi A; Ruifrok WT; Karageorgiev D; Aminian A; Garducci S; Merkely B; Routledge H; Ando K; Diaz Fernandez JF; Cuisset T; Nesa Malik FT; Halabi M; Belle L; Din J; Beygui F; Abhyankar A; Reczuch K; Pedrazzini G; Heg D; Vranckx P;
    Eur Heart J; 2022 Sep; 43(33):3100-3114. PubMed ID: 35580836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
    Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
    Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-Year follow-up results of the REDUCE trial.
    Kedhi E; Verdoia M; Suryapranata H; Damen S; Camaro C; Benit E; Barbieri L; Rasoul S; Liew HB; Polad J; Ahmad WA; Zambahari R; Lalmand J; van der Schaaf RJ; Koh TH; Timmermans P; Dilling-Boer D; Veenstra LF; Van' T Hof AW; Lee SW; Roolvink V; Ligtenberg E; Postma S; Kolkman EJ; Brouwer MA; Dudek D; De Luca G
    Atherosclerosis; 2021 Mar; 321():39-44. PubMed ID: 33639478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing the optimal duration of DAPT following PCI in high-risk TWILIGHT-like patients with acute coronary syndrome.
    Wang HY; Mo R; Guan CD; Wang Y; Zhao YY; Xie LH; Zhang R; Cai ZX; Xu B; Dou KF
    Catheter Cardiovasc Interv; 2022 Jan; 99(1):98-113. PubMed ID: 33909311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients.
    Han J; Zhang Y; Shi X; Lin B; Zhang Y; Zhang R; Wang Y; Yan J; Lin Y
    Glob Heart; 2023; 18(1):11. PubMed ID: 37228657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
    D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
    Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Antiplatelet Therapy Duration in Medically Managed Acute Coronary Syndrome Patients: Sub-Analysis of the OPT-CAD Study.
    Ma S; Jiang Z; Qiu M; Li Z; Bian L; Li Y; Han Y
    Adv Ther; 2020 Jul; 37(7):3150-3161. PubMed ID: 32418142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention.
    Faggioni M; Baber U; Sartori S; Chandrasekhar J; Cohen DJ; Henry TD; Claessen BE; Dangas GD; Gibson CM; Krucoff MW; Vogel B; Moliterno DJ; Sorrentino S; Colombo A; Chieffo A; Kini A; Farhan S; Ariti C; Witzenbichler B; Weisz G; Steg PG; Pocock S; Mehran R
    Circ Cardiovasc Interv; 2019 Apr; 12(4):e007133. PubMed ID: 30998384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged dual antiplatelet therapy in invasively treated acute coronary syndrome patients with different lipoprotein(a) concentrations.
    Cui K; Wu S; Yin D; Song W; Wang H; Zhu C; Feng L; Yang Y; Fu R; Dou K
    Cardiol J; 2024; 31(1):32-44. PubMed ID: 37853822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial.
    Verdoia M; Suryapranata H; Damen S; Camaro C; Benit E; Barbieri L; Rasoul S; Liew HB; Polad J; Ahmad WAW; Zambahari R; Lalmand J; van der Schaaf RJ; Koh TH; Timmermans P; Dilling-Boer D; Veenstra LF; Van't Hof AWJ; Lee SWL; Roolvink V; Ligtenberg E; Postma S; Kolkman EJJ; Brouwer MA; Kedhi E; De Luca G
    J Thromb Thrombolysis; 2021 Oct; 52(3):797-807. PubMed ID: 33847862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term dual antiplatelet-induced intestinal injury resulting in translocation of intestinal bacteria into blood circulation increased the incidence of adverse events after PCI in patients with coronary artery disease.
    Zheng YY; Wu TT; Guo QQ; Chen Y; Ma X; Ma YT; Zhang JY; Xie X
    Atherosclerosis; 2021 Jul; 328():1-10. PubMed ID: 34052667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
    Kim BK; Hong SJ; Cho YH; Yun KH; Kim YH; Suh Y; Cho JY; Her AY; Cho S; Jeon DW; Yoo SY; Cho DK; Hong BK; Kwon H; Ahn CM; Shin DH; Nam CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y;
    JAMA; 2020 Jun; 323(23):2407-2416. PubMed ID: 32543684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of dual antiplatelet therapy in patients presented with acute coronary syndrome vs. stable ischaemic heart disease after coronary artery bypass grafting.
    Choi KH; Song YB; Jeong DS; Jang YH; Hong D; Lee SY; Youn T; Bak M; Min KM; Lee JM; Park TK; Yang JH; Hahn JY; Choi JH; Choi SH; Chung SR; Cho YH; Sung K; Kim WS; Gwon HC; Lee YT
    Eur Heart J Cardiovasc Pharmacother; 2021 Nov; 7(6):517-526. PubMed ID: 33075126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of extended dual antiplatelet therapy on clinical prognosis in acute coronary syndrome patients with intermediate or high ischemic risk defined by the GRACE score.
    Bian L; Qiu M; Li Y; Xu X; Li J; Ma S; Qi Z; Han Y
    Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():665-673. PubMed ID: 31957965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
    Song PS; Park YH; Oh JH; Song YB; Choi SH; Gwon HC; Cho DK; Rha SW; Bae JW; Jeong JO; Hahn JY;
    Am J Cardiol; 2021 Jul; 150():47-54. PubMed ID: 34011436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Efficacy and Safety of Duration of Dual Antiplatelet Therapy in Patients with CAD Undergoing Drug-eluting Stent Implantation: A Systematic Review and Network Meta-analysis.
    Guan J; Song W; He P; Fan S; Zhi H; Wang L
    Curr Pharm Des; 2020; 26(44):5739-5745. PubMed ID: 32586248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.